If you have been researching prescription weight loss injections, you have probably come across Wegovy and Ozempic. Because both medicines contain the same active ingredient, semaglutide, many people assume they are interchangeable. However, while they are closely related, they are not licensed for the same purpose in the UK, so it is important to understand the differences before starting treatment.
If you are considering medically supervised weight management, you may be wondering whether Wegovy or Ozempic is the right option. The answer depends on several factors, including the condition being treated, each medicine's MHRA licence, the available dosage strengths, clinical evidence, and your healthcare professional's assessment.
This guide explains the key differences between Wegovy and Ozempic in the UK, including how each medicine is licensed and used in UK clinical practice, why licensing matters, and what you can expect if you are seeking treatment for weight management. Whether you are comparing effectiveness, treatment options, or practical considerations, this page provides evidence based information to help you make an informed decision.
Wegovy vs Ozempic at a Glance
Although Wegovy and Ozempic both contain semaglutide, they are licensed for different medical purposes in the UK.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| MHRA licence | Chronic weight management | Type 2 diabetes |
| Primary purpose | Weight management alongside a reduced-calorie diet and increased physical activity | Blood sugar management |
| Weekly injection | Yes | Yes |
| Prescription required | Yes, with a valid prescription | Yes |
| Lifestyle support recommended | Yes | Yes |
The biggest distinction is regulatory approval. Wegovy has been specifically evaluated and authorised for chronic weight management, whereas Ozempic is a prescription-only medication licensed in the UK to improve blood glucose control in adults with type 2 diabetes, so prescribing Ozempic solely for weight management would generally be considered off-label use .
Although both medicines share the same active ingredient, they should only be prescribed for approved clinical indications and under appropriate medical supervision.
Are Wegovy and Ozempic the Same Medicine?
One of the most common misconceptions is that Wegovy and Ozempic are the same medicine with different names.
In reality, they contain the same active ingredient, semaglutide, but they have been developed, studied, and licensed for different purposes.
Wegovy was developed and clinically evaluated as a treatment for obesity and overweight in people with weight related health conditions. Its clinical studies looked at its use alongside a reduced calorie diet and increased physical activity in eligible adults.
Ozempic, by contrast, was developed primarily to help improve blood glucose control in adults with type 2 diabetes. Although some people may experience weight loss during treatment, this is not the reason it is licensed in the UK. Using Ozempic for weight loss in the UK would generally be considered an off label use rather than a licensed weight management treatment.
Understanding this difference can help you compare information more confidently and have informed discussions with your healthcare professional about your treatment options.
Why MHRA Licensing Matters
Medicines available in the UK must be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be prescribed for specific conditions.
The licensing process evaluates:
- Patient safety
- Appropriate dosing schedules
- Potential risks and benefits
- Quality standards during manufacturing
For people seeking weight management treatment, this means Wegovy has been clinically evaluated for obesity, while Ozempic is licensed for the management of type 2 diabetes.
Using a medicine that is licensed for your condition helps ensure treatment follows established clinical guidance and regulatory standards.
Who Is Wegovy Intended For?
Wegovy is a prescription medicine for weight management in eligible adults and may be prescribed at licensed doses of up to 2.4 mg once weekly, where appropriate.
Treatment may be considered for people who:
- Have a Body Mass Index (BMI) of 30 kg/m² or above
- Have a BMI of 27 kg/m² or above with a weight related medical condition, such as hypertension or obstructive sleep apnoea
Treatment is intended to be used alongside:
- A reduced calorie eating plan
- Increased physical activity
- Long term lifestyle changes
- Regular clinical review
Eligibility and prescribing, including whether Wegovy is appropriate, must be assessed by a registered doctor or other qualified prescriber following a clinical assessment. Treatment should be used alongside a reduced calorie diet and increased physical activity.
Who Uses Ozempic?
Ozempic is primarily prescribed for adults with type 2 diabetes and contains the active ingredient semaglutide.
Its main treatment goals include:
- Helping improve blood glucose control in adults with type 2 diabetes
- Supporting HbA1c reduction
- Complementing a healthy diet and regular exercise
- Helping manage high blood sugar levels in appropriate patients
The usual starting dose is 0.25 mg once weekly. The dose may be increased if additional blood glucose control is needed, as determined by the prescribing healthcare professional.
Although some people taking Ozempic may experience weight loss, this does not change its licensed use in the UK.
Healthcare professionals prescribe Ozempic based on an individual's diabetes management needs rather than for weight management alone.
Why UK Patients Compare Wegovy and Ozempic
There are several reasons why these medicines are often compared online.
Many people notice that:
- Both contain semaglutide
- Both are taken once weekly
- Both are available as easy to use injection pens
- Both affect appetite and food intake
However, despite these similarities, it is important not to assume the medicines are interchangeable.
The decision about which medicine may be appropriate depends on:
- Your medical history
- The condition being treated
- Current medications
- Clinical eligibility
- UK prescribing guidance
- Advice from a qualified healthcare professional
A clinical assessment by a registered healthcare professional is the best way to determine which treatment option may be suitable for you.
Comparing the Patient Journey
Although Wegovy and Ozempic are administered using similar injection devices, the overall patient experience differs because the treatment objectives are different.
Wegovy focuses on:
- Long term weight management
- Appetite regulation
- Structured dose escalation, with progression to higher doses carried out under clinical supervision. Wegovy has been studied at higher maintenance doses than Ozempic, in line with its licensed use for weight management
- Lifestyle modification
- Long term follow up, as ongoing support may help with maintaining weight management after treatment ends
- Ongoing weight monitoring
In certain eligible adults with established cardiovascular disease and obesity or overweight, Wegovy is licensed to reduce the risk of major adverse cardiovascular events
Ozempic focuses on:
- Type 2 diabetes management with blood sugar management.
- Blood glucose control.
- Monitoring blood sugar levels.
- Diabetes care planning.
- Metabolic health management.
This difference influences how patients are monitored throughout treatment and what outcomes healthcare professionals assess during follow-up appointments.
Key Takeaways Before Choosing Treatment
Before deciding between Wegovy and Ozempic, remember these important points:
- Both medicines contain semaglutide.
- They are not licensed for the same purpose.
- Wegovy is authorised for chronic weight management.
- Ozempic is authorised for type 2 diabetes.
- Both require a prescription.
- Clinical assessment is essential before treatment begins.
- Lifestyle changes remain an important part of successful long-term outcomes.
Understanding these differences helps patients have more informed conversations with healthcare professionals and choose treatment based on clinical need rather than product familiarity.
How Semaglutide Works in the Body
One reason Wegovy and Ozempic are often compared is because both medicines contain semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist. GLP 1 is a natural hormone released by the intestine after eating. It helps regulate appetite, food intake, and glucose metabolism.
When semaglutide is given as a once weekly injection, it mimics the action of this hormone by activating GLP 1 receptors. These effects may help some people:
- Feel fuller after smaller meals
- Experience reduced hunger between meals
- Slow gastric emptying, allowing food to remain in the stomach for longer
- Reduce cravings for high calorie foods
- Support a calorie controlled eating plan
Although both medicines work in a similar way, they are licensed for different purposes. Wegovy has been studied and licensed for chronic weight management, while Ozempic is licensed to help improve glycaemic control in adults with type 2 diabetes.
Clinical Evidence: What the STEP Trials Tell Us
The strongest evidence for Wegovy in weight management comes from the internationally recognised STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme.
These studies evaluated Wegovy in thousands of adults living with overweight or obesity and assessed its effects when used alongside lifestyle changes.
STEP 1 Trial
The landmark STEP 1 study, published by Wilding et al. in the New England Journal of Medicine (2021), found that participants who received Wegovy alongside a reduced calorie diet and increased physical activity achieved an average weight loss of around 15% of their starting body weight after 68 weeks, compared with 2.4% in the placebo group.
STEP 3 Trial
STEP 3 combined Wegovy with intensive behavioural therapy and structured lifestyle support. Participants achieved average weight loss of approximately 16%, highlighting the benefits of combining medication with comprehensive lifestyle changes.
STEP 5 Trial
Long-term follow-up demonstrated that patients who continued treatment maintained clinically significant weight reduction over 104 weeks, reinforcing the importance of ongoing therapy and regular clinical review. In routine weight management, long-term therapy often continues at a maintenance dose, with Wegovy typically used at 2.4 mg once weekly.
These studies formed the scientific foundation for Wegovy's approval for chronic weight management.
Why Dose Escalation Matters
Unlike many medicines that begin at the full therapeutic dose, Wegovy follows a carefully structured dose-escalation programme that begins with a starting dose and builds gradually to the maintenance dose.
Patients generally progress through:
| Treatment Phase | Weekly Dose |
|---|---|
| Weeks 1–4 | 0.25mg |
| Weeks 5–8 | 0.5mg |
| Weeks 9–12 | 1mg |
| Weeks 13–16 | 1.7mg |
| Week 17 onwards | 2.4mg |
A weekly dose of 2.4mg is the maximum maintenance dose, and patients should only move up if advised by their prescriber.
This gradual increase allows the body to adapt to semaglutide while helping to reduce the likelihood of gastrointestinal side effects during the early stages of treatment.
The schedule used in routine clinical practice reflects the protocol evaluated throughout the STEP programme.
Wegovy vs Ozempic: Dosing Comparison
Although both medicines contain semaglutide, their licensed dosing pathways differ because they are intended for different treatment goals.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Licensed indication | Weight management | Type 2 diabetes |
| Maximum licensed UK dose | 2.4mg weekly in UK licensed use; do not exceed the prescribed maximum dose | Lower licensed diabetes doses* |
| Standard escalation | Five-stage programme | Starts at 0.25mg weekly and is increased gradually toward the correct dose for diabetes management |
| Clinical focus | Appetite regulation and weight management | Blood glucose control |
*Always follow your prescriber's instructions and the approved product information for your prescribed medicine.
These differences highlight why treatment decisions should always be based on clinical assessment rather than simply comparing the active ingredient.
Side Effects: Similarities and Differences
Because Wegovy and Ozempic both contain semaglutide, they share many of the same potential side effects.
Commonly reported side effects include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
- Reduced appetite
These symptoms are often more noticeable during dose escalation and may improve as your body adjusts to treatment. Acute pancreatitis is a rare but serious side effect, and symptoms that may suggest pancreatitis require urgent medical attention.
You should seek medical advice and speak to your doctor or prescriber if you experience severe abdominal pain, persistent vomiting, or symptoms that may suggest low blood sugar, particularly if semaglutide is used with other diabetes medicines.
Your prescriber can explain how to manage common side effects and advise whether any changes to your treatment are needed.
Comparing Treatment Goals
Although patients often focus on the medication itself, the intended treatment outcomes differ considerably.
Wegovy Treatment Goals
- Supports long-term weight management .
- Appetite regulation.
- Support for a healthy diet and diet and exercise plan as part of sustainable lifestyle changes.
- Improved weight-related health outcomes.
- Ongoing weight management support.
Ozempic Treatment Goals
- Improved blood glucose control
- HbA1c reduction
- Support for diabetes management
- Support for long term metabolic control
Understanding these different treatment goals helps explain why healthcare professionals may choose one medicine over another based on an individual's clinical needs.
Pricing and Treatment Planning
When comparing Wegovy and Ozempic privately, cost is naturally an important consideration. However, treatment should always be selected based on clinical suitability, not simply on price.
At EverydayMeds, Wegovy is available with transparent pricing across all licensed strengths, helping patients understand the cost of treatment at each stage from the introductory dose through to long-term maintenance.
Current pricing includes:
| Wegovy Dose | Price |
|---|---|
| 0.25mg | From £79.99* |
| 0.5mg | £94.99 |
| 1mg | £99.99 |
| 1.7mg | £139.99 |
| 2.4mg | £209.99 |
Eligible new customers can use promotional offers where available. Bundle options may be available for patients who wish to plan several weeks or months of treatment in advance, helping support continuity throughout the recommended dose-escalation programme.
Which Medicine Is Used for Weight Management in the UK?
For adults seeking medically supervised weight management, Wegovy is the medicine licensed in the UK for this purpose.
Healthcare professionals may consider factors such as:
- Body Mass Index (BMI)
- Weight related health conditions
- Previous weight management approaches
- Current medications
- Medical history
- Potential contraindications
A qualified prescriber will review this information before deciding whether Wegovy is an appropriate treatment option.
You should not switch between Wegovy and Ozempic without advice from a qualified healthcare professional, even though both medicines contain semaglutide.
Choosing the Right Treatment for Your Health Goals
Deciding between Wegovy and Ozempic should not be based only on online reviews or social media discussions. Although both medicines contain semaglutide, they are licensed for different purposes, and the most appropriate option depends on your individual health needs and treatment goals.
If you are seeking treatment for weight management, Wegovy is the medicine licensed in the UK for this purpose. If you are being treated for type 2 diabetes, your healthcare professional may recommend Ozempic as part of your diabetes management plan.
Rather than asking which medicine is "better", it is more helpful to ask which treatment may be appropriate for your individual needs. A qualified prescriber will consider factors such as your BMI, medical history, current medications, previous treatment approaches, and any underlying health conditions before recommending a treatment option.
How to Get Wegovy Through EverydayMeds
At EverydayMeds, accessing Wegovy is designed to provide a convenient clinical assessment process while maintaining the highest standards of patient safety.
Step 1 – Complete an Online Clinical Assessment
Your journey begins with a secure online questionnaire that takes around three minutes to complete.
The assessment covers:
- Height and weight.
- Medical history.
- Current medications.
- Existing health conditions.
- Previous weight management treatments.
- Lifestyle goals.
Providing accurate information allows our clinical team to assess whether Wegovy is suitable for you.
Step 2 – Prescriber Review
Once submitted, your assessment is reviewed by a qualified UK prescriber.
Most reviews are completed within approximately three working days , while an express review service may be available for eligible patients requiring a faster decision.
Every prescription is assessed individually to ensure treatment is clinically appropriate.
Step 3 – Pharmacy Dispensing
Following approval, your prescription is prepared by our GPhC-registered pharmacy (#9012878).
Approved patients receive genuine MHRA-authorised medicine dispensed against a valid prescription from a registered doctor, rather than through unverified supply routes.
Before dispatch, medication is checked and packaged using temperature-controlled materials to help maintain the manufacturer's recommended storage conditions.
Step 4 – Temperature-Controlled Delivery
Approved prescriptions are dispatched using specialist cold-chain delivery services.
This helps ensure your Wegovy arrives under the recommended temperature conditions, ready for safe storage upon delivery.
Tracking information is provided so you can monitor your order throughout the delivery process.
Storage and Everyday Use
Correct storage is essential for maintaining the quality of Wegovy.
Before First Use
- Refrigerate between 2°C and 8°C.
- Store inside the original carton.
- Protect from light.
- Keep the pen cap on when not in use.
- Read the patient information leaflet before first use for full storage and handling guidance.
- Never freeze.
After Removing from the Refrigerator
According to the manufacturer's guidance, Wegovy may be stored below 30°C for up to six weeks in accordance with the manufacturer's instructions for up to six weeks.
Patients should avoid exposing the pen to excessive heat, direct sunlight, or freezing temperatures.
Why Patients Choose EverydayMeds
Choosing a regulated online pharmacy offers more than convenience. It helps give you confidence that your treatment is prescribed and supplied in line with UK healthcare standards.
EverydayMeds offers:
- MHRA licensed Wegovy for eligible patients
- Assessments by qualified UK prescribers
- GPhC registered pharmacy services
- Transparent pricing across all dose strengths
- Secure online consultations
- Next day temperature controlled delivery, where available
- Bundle options to support ongoing treatment
- Ongoing clinical and customer support throughout your weight management journey
Our aim is to provide a convenient online service with appropriate clinical oversight, helping eligible patients access treatment following an individual clinical assessment.
